Just-Evotec Biologics

Cambria Corporation, based in Seattle, WA, has been a leader in providing innovative technological solutions for over 35 years. The company specializes in the design, development, and manufacture of custom sensors and systems, serving sectors such as telecommunications, environmental monitoring, and material handling. As a nimble and vertically-integrated organization, Cambria is certified ISO 9001:2015 and employs Lean Enterprise and Six Sigma concepts to ensure high-quality products. Their offerings include RF testing units, environmental sensors, and advanced material handling systems, catering to the specific needs of their OEM clients. Generated from the website

Clear Water Services, based in Everett, WA, specializes in providing innovative water treatment solutions tailored to the unique needs of various industries. With 27 years of experience, the company has successfully completed over 2,095 projects and treated 7 billion gallons of water. Their extensive range of services includes treatability studies, permitting and design support, custom equipment fabrication, and Washington State-certified training programs. Clear Water Services is committed to identifying efficient and cost-effective approaches to meet its clients' water management challenges across sectors such as construction, aerospace, and energy. Generated from the website

Icosavax, Inc. is a clinical-stage biotechnology company based in Seattle, WA, dedicated to developing innovative vaccines using their unique virus-like particle (VLP) technology. Their VLPs are designed to mimic the structure of viruses, offering potential advantages such as a stronger immune response, broader coverage against related viral strains and mutations, longer durability, and easier combinability for multiple targets in one vaccine. With a focus on protecting vulnerable older adults from respiratory viruses, Icosavax aims to revolutionize the field of vaccines by creating a new era of immunization. Their cutting-edge approach has garnered attention, leading to an agreement to be acquired by AstraZeneca and positive interim Phase 2 results for their combination VLP vaccine candidate, IVX-A12, against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.Generated from the website